Novartis AG Stops Tasigna Trial in Patients with GIST

ZURICH, April 11 (Reuters) - Novartis AG (NOVN.VX) has stopped a late-stage trial for Tasigna in intestinal tumors after a committee said the cancer drug was unlikely to show it was more effective than Glivec, the current standard of care.